Dr. Premal H Thaker, M.D., M.S.

About Premal H Thaker, M.D., M.S.

Education:

• Completed a combined BSc/MD program at Villanova University.
• Earned an MD degree from Allegheny University in Philadelphia.

Experience:

• Completed a Residency in OB/GYN at the Hospital of the University of Pennsylvania.
• Undertook a Fellowship in Gynecologic Oncology at M. D. Anderson Cancer Center.
• Served as an Assistant Professor at Washington University in St. Louis since 2006, promoted to Professor in 2018.
• Appointed as the inaugural David & Lynn Mutch Distinguished Professor of Obstetrics and Gynecology at Washington University School of Medicine.
• Director of Gynecologic Oncology Clinical Trials and Clinical Research at Washington University School of Medicine.
• Recognized for outstanding patient care, consistently named to the St. Louis Best Doctor's list since 2013 and Castle Connolly since 2021.

Area of expertise

Affiliated Hospitals

Washington University School Of Medicine

Washington University School Of Medicine

Clinical Trials Premal H Thaker, M.D., M.S. is currently running

Olvi-Vec + Chemotherapy

for Ovarian Cancer

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.

Recruiting

2 awards

Phase 3

7 criteria

Selumetinib + Olaparib

for Ovarian and Endometrial Cancer

This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.

Recruiting

1 award

Phase 2

More about Premal H Thaker, M.D., M.S.

Clinical Trial Related

3 years of experience running clinical trials · Led 35 trials as a Principal Investigator · 11 Active Clinical Trials

Other Doctors you might be interested in

Frequently asked questions